Net Deals Web Search

Search results

1. Results From The WOW.Com Content Network

2. Novartis lifts profit forecast for second time on Cosentyx ...

   www.aol.com/news/novartis-raises-2024-profit...

   Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure treatment Entresto and arthritis ...

3. Novartis raises sales growth target to 5% a year through 2027

   www.aol.com/news/novartis-lifts-sales-growth...

   FRANKFURT (Reuters) -Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business. The medium-term ...

4. Exclusive-Novartis in the lead to acquire cancer drug ... - AOL

   www.aol.com/news/exclusive-novartis-lead-acquire...

   By David Carnevali (Reuters) -Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two ...

5. Vasant Narasimhan - Wikipedia

   en.wikipedia.org/wiki/Vasant_Narasimhan

   He spent 8 years working in Novartis Vaccines, at the time a non-profit division focused on developing vaccines for children and patients around the world and served as the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables.

6. Novartis in advanced talks to buy Cytokinetics- source - AOL

   www.aol.com/news/novartis-advanced-talks-buy...

   (Reuters) -Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

7. Nilotinib - Wikipedia

   en.wikipedia.org/wiki/Nilotinib

   Nilotinib is a Bcr-Abl tyrosine kinase inhibitor and works by interfering with signalling within the cancer cell. [ 5] Nilotinib was approved for medical use in the United States in 2007. [ 5] It is on the World Health Organization's List of Essential Medicines. [ 6] It is approved as a generic medication.

8. Novartis Gene Therapies - Wikipedia

   en.wikipedia.org/wiki/Novartis_Gene_Therapies

   Novartis Gene Therapies, until 2020 known as AveXis, is a biotechnology company that develops treatments for rare neurological genetic disorders. It was founded in Dallas , Texas , United States in 2012 by John Carbona after reorganizing a company called BioLife Cell Bank founded by David Genecov and John Harkey.

9. Novartis begins tender offer for cancer-focused MorphoSys - AOL

   www.aol.com/news/novartis-begins-tender-offer...

   BERLIN (Reuters) -Novartis said on Thursday it has launched a tender offer to acquire MorphoSys, a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion).